Axel Grothey1, Daniel J Sargent2. Show Affiliations » 1. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/therapeutic useAntineoplastic Agents/therapeutic useAntineoplastic Combined Chemotherapy Protocols/therapeutic useCetuximab/therapeutic useChemotherapy, AdjuvantColonic Neoplasms/drug therapyColonic Neoplasms/geneticsColonic Neoplasms/pathologyFluorouracil/administration & dosageGTP Phosphohydrolases/geneticsGenotypeHumansMembrane Proteins/geneticsMicrosatellite InstabilityNeoplasm StagingNivolumabOrganoplatinum Compounds/administration & dosageOxaliplatinPanitumumabPhenotypePrecision MedicineProto-Oncogene Proteins B-raf/geneticsProto-Oncogene Proteins p21(ras)/genetics
Substances： See more » Antibodies, MonoclonalAntineoplastic AgentsKRAS protein, humanMembrane ProteinsOrganoplatinum CompoundsOxaliplatinNivolumabPanitumumabBRAF protein, humanProto-Oncogene Proteins B-rafGTP PhosphohydrolasesNRAS protein, humanProto-Oncogene Proteins p21(ras)CetuximabFluorouracil
Year: 2016 PMID： 27273467 DOI： 10.1001/jamaoncol.2016.2304
Source DB: PubMed Journal: JAMA Oncol ISSN： 2374-2437 Impact factor: 31.777